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INTRODUCTION:  Interphalangeal  joint  of  foot  is  a very  unusual  location  for  gouty  arthritis  and  sildenaﬁl
use  may  cause  this  phenomenon.
PRESENTATION OF  CASE:  A  58-year-old  hypertensive  man  was  admitted  to hospital  with  pain  and  swelling
over  interphalengeal  joint  of his  right  great  toe.  His  health  history  included  the  use  of diuretics  for  a  long
time  and his  last  gout  attack  was  two  years  ago  at ﬁrst  metatarsophalengeal  joint  of  right foot.  Sildenaﬁl,
a  selective  inhibitor  of  phosphodiesterase  type  5 (PDE5),  was  administered  in  case  of  erectile  dysfunction
for  two  months.  Subsequently,  he  had  several  episodes  of pain  and  swelling  at ﬁrst  interphalangeal  joint
of  right  great  toe.  Both  the  onset  and  recurrence  of symptoms  were  just  seen  the  day  after  sildenaﬁl  use.
The  patient  was  free of symptoms  after  discontinuation  of  the  drug.  After  an  initial  evaluation,  gout  was
diagnosed  on  the  basis  of  synovial  ﬂuid  analysis.
DISCUSSION: This  case  demonstrates  a rare  location  of  gouty  arthritis  with  an  uncommon  etiology:  sil-
denaﬁl.  Regarding  the clinical  data,  the  discussion  was made  to expand  the horizon  for  diagnosis  of
patients  with  similar  symptoms,  to  identify  risk  factors  for  gout  relevant  to  elderliness,  and  to  review  the
management  of  gout.
CONCLUSION: Sildenaﬁl  use  may  cause  gouty  arthritis,  and  surgical  decompression  may  be  helpful  for
deﬁnitive  diagnosis  and  symptom  relief  in  atypical  presentation  of  gout.
gical © 2012 Sur
. Introduction
Gout is a clinical condition affecting 1% of adult males in devel-
ped countries.1 It is the most common cause of inﬂammatory joint
isease in men  aged over 40 years.1 Deposition of monosodium
rate monohydrate crystals into joint and soft tissue is the under-
ying pathology and there is a causative relationship between
levated blood uric acid level and urate crystal formation. Although
he exact trigger mechanism of an acute attack is poorly under-
tood, predictors for the development of gout in hyperuricemic
ndividuals have been identiﬁed.2 These include increased uric
cid level, alcohol consumption, hypertension, use of drugs espe-
ially antihypertensives, increased body mass index, and family
istory of gout.2–4 Sildenaﬁl, a selective inhibitor of cyclic guano-
ine monophosphate (cGMP)-speciﬁc phosphodiesterase type 5
PDE5), may  rarely cause gouty arthritis.5 Gout can either mani-
est as acute arthritis or chronic arthropathy, which is also called
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tophaceous gout.1,6 Gouty arthritis is most commonly seen at
metatarsophalangeal joint. We here report an uncommon case of
tophus formation at ﬁrst interphalengeal joint of foot, probably due
to sildenaﬁl use.
2.  Case presentation
A  58-year-old male patient was  admitted to hospital with two-
month history of moderate pain and swelling over interphalangeal
joint of his right great toe, which was  affecting shoewear. The pain
was out of proportion with swelling and worse at nights after using
medication for erectile dysfunction. He had visited two primary
care physicians before admission and was prescribed pain killers
for his acute symptoms. His health history included two  previ-
ous episodes of gout in both ﬁrst metatarsophalangeal joints (2
and 4 years prior), hypertension and coronary artery disease for
8 years. His medications were perindopril (4 mg), hydrochloroth-
iazide (25 mg), salicylic acid (100 mg), allopurinol (800 mg) and
colchicine (0.5 mg). He denied smoking, but occasional alcohol use
was noted on every weekend. He was not on any particular diet.
Due to erectile dysfunction, he has taken 100 mg  sildenaﬁl p.o.
weekly for 2 months and was  still on medication just before the
Open access under CC BY-NC-ND license.day of admission. Any contributory family history or allergy history
were not noted. Physical examination revealed 3 cm × 2 cm tender
swelling without cellulitis or ulceration over dorsomedial aspect of
ﬁrst interphalengeal joint of right foot (Picture 1). Joint motion was
 BY-NC-ND license.
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Fig. 1. Plain radiography of right foot showing joint effusion, and soft tissue swelling
around  ﬁrst interphalengeal joint.icture 1. Swelling over dorsomedial aspect of ﬁrst interphalengeal joint of right
oot.
xtremely limited due to pain and swelling. There were no other
wellings or tophi noted especially on ears or other joints. He had
n average built with body mass index (BMI) of 27.4.
Plain radiography of right foot showed joint effusion, and soft
issue swelling around ﬁrst interphalengeal joint (Fig. 1). Labora-
ory data were within normal limits (Table 1). In the operating
oom, surgical decompression of ﬁrst interphalangeal joint of his
ight foot was performed with a dorsomedial incision over swelling
Pictures 2 and 3). Debris consisted of thick, chalky, white material
orresponding to gouty tophus (Picture 2). The surgical approach
as adequate to expose the articular surfaces. After debridement
nd vigorous irrigation with sterile saline solution, intraarticular
ethyprednisolone 20 mg  was injected to the affected site. Incision
as gently sutured without tightening. Additional indomethacin
0 mg  was prescribed three times daily for 10 days. His pain scale
as 7/10 and 3/10 before and after surgery, respectively. Syno-
ial ﬂuid analysis was conﬁrmatory (Table 2). Light microscopy of
ebris demonstrated gouty tophi consisting of monosodium urate
able 1
aboratory data at admission.
Test Value Value range
WBC  8200 mm3 4–10
Hemoglobin 12.1 g/dl 12.5–16.5
Sodium 141 meq/l 135–145
Potassium 3.9 meq/l 3.5–4.9
Chloride 105 meq/l 96–110
BUN 19 mg/dl 6.0–23.0
Creatinine 0.8 mg/dl 0.6–1.4
Total protein 5.4  g/dl 6.0–8.0
Albumin 3.7 g/dl 3.6–5.0
Calcium 8.2 mg/dl 8.0–10.5
Hemoglobin 11.6 g/dl 12.6–16.5
Platelet count 236,000 mm3 150–400
Uric acid 6.4 mg/dl 3.4–7.0
Picture 2. Debris consisting of thick, chalky, white material corresponding to gouty
tophus.
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Fig. 2. Light microscopy of debris demonstrating gouty tophi consisting of
monosodium  urate crystals.Picture 3. Closure of dorsomedial incision after decompression.
rystals (Fig. 2). Microscopic examination of the specimen revealed
olynuclear giant cells and histiocytes around needle-like void
paces and granular nodule formation was seen (Fig. 3). Wound
ealing was observed on day 18 without complication. The patient
as free of symptoms at 2 months, postoperatively.
. Discussion
Gout is a metabolic disease that can manifest as acute or chronic
rthritis with deposition of urate crystals in connective tissue and
idneys. Gouty tophi are commonly found in articular and other
artilages; in synovium, tendon sheaths, and other periarticular
tructures; in epiphyses, and in subcutaneous layers of the skin
n the extremities. Tophi are most often seen in tissues that have a
oor blood supply and low temperature, such as the ear helix and
rst metatarsophalengeal joint.7 The nodules are yellowish-white,
nd non-tender, and range in size from 1 mm to 7 cm.  Aspiration
ields a chalky-like material that appears as needle-like crystals
nder light microscopy. All patients have hyperuricemia at some
oint of their disease. Hyperuricemia results from either decreased
enal excretion (which occurs in 90% of gout patients) or hyperpro-
uction of uric acid.8 Drugs that may  cause hyperuricemia and gout
able 2
ynovial ﬂuid analysis.
Test Value Normal
Clarity Translucent Transparent
Color Whitish Yellow Clear
WBC (per mm3) 2000 <200
PMNs (%) 55 <25
Gram stain No organisms No organisms
Culture Negative Negative
Total protein (g/dl) 1.9 3.1
LDH (IU/l) 494 105–330
Glucose (mg/dl) 44 70–110
Crystal Monosodium urate crystals None
Fig. 3. Microscopic examination of the specimen revealing polynuclear giant cells
and histiocytes around needle-like void spaces and granular nodule formation.
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nclude diuretics, cyclosporine, low-dose aspirin, ethambuthol,
yrzinamide, and nicotinic acid.9 Sildenaﬁl, a selective inhibitor
f cyclic guanosine monophosphate (cGMP)-speciﬁc phosphodie-
terase type 5 (PDE5), may  also play a role in the etiology.5 In
re-marketing clinical trials over 3700 patients, rare adverse events
eported with sildenaﬁl in adults (all <2%) include arrhythmias,
erebral thrombosis, hypertonia, paresthesias, priapism, migraine,
remor, photosensitivity, colitis, vomiting, abnormal liver func-
ion tests, anemia, leukopenia, gout, arthritis, dyspnea, and allergic
eactions.5 Exact mechanism of sildenaﬁl to trigger a gout attack
s not known, but PDE5 is also found in platelets, vascular and
isceral smooth muscle, and skeletal muscle in addition to cor-
us cavernosum. Inhibition of PDE5 in these tissues by sildenaﬁl
ay increase antiaggregatory activity of nitric oxide and periph-
ral arterial-venous dilatation.5 Chen et al. reported a case of acute
outy arthritis at ﬁrst metatarsophalengeal joint after taking sil-
enaﬁl. The patient had several attacks only after administration
f sildenaﬁl, implying a causal relation between sildenaﬁl and gout
pisodes.10 Since our patient’s last attack was two years ago, and
oth the onset and recurrence of symptoms were just seen the
ay after sildenaﬁl use, it was considered that there was a causal
elation with detoriation of symptoms and the medication. Fur-
hermore, our case had gout attacks at interphalengeal joint of
ight great toe which is very uncommon location for gouty arthri-
is. Literature review yielded only one case of gouty arthritis at
nterphalangeal joint of big toe that is reported as an atypical pre-
entation of gout by Dobson et al.11
As some are commonly prescribed, it is important that
hysicians dealing with musculoskeletal diseases and erectile dys-
unction must be aware of the medications that their patients are
aking. So far, increasing attention has been drawn to the role
layed by diuretics in the pathogenesis of gout, particularly in the
lderly, however, the use of phosphodiesterase inhibitors may  also
ontribute to the progression of disease. Gouty arthritis is caused
y intense inﬂammation secondary to monosodium urate crystal
eposition in joints. Tophus is often found in the auricular car-
ilage or metatarsophalengeal joint of great toe. We  presented a
atient with gouty tophus formation at the ﬁrst interphalengeal
oint of his right foot. Local factors that contribute to tophus forma-
ion are changes in perioperative pH level, lower body temperature,
xplaining nocturnal attacks; and the level of articular dehydration
ue to diuretics.8 The goals of gout treatment are symptom control
or acute attacks, risk factor modiﬁcation, pharmacotherapy to pre-
ent recurrence and chronic sequelae in the long run, and surgical
ecompression of tophi for pain management.
Tophaceous gout may  lead to signiﬁcant morbidity and, if
ntreated, can cause joint erosion and destruction.9 Tophaceous
aterial may  present in a liquid, pasty, or chalky/granular state.
reatment may  be as simple as aspirating the liquid or squeez-
ng out pasty tophaceous material. Surgery is often indicated for
he patient with signiﬁcant tendon and joint compromise as well
s skin breakdown. Surgical decompression followed by optimiza-
ion of pharmacologic treatment and lifestyle modiﬁcation provide
ood recovery.
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Conclusion
Sildenaﬁl use may rarely cause gouty arthritis. Interphalengeal
joint involvement of great toe is atypical for gout and surgical
decompression may  be helpful for deﬁnitive diagnosis and symp-
tom relief.
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